Knee Cartilage Repair

REPORT HIGHLIGHTS

Global Knee Cartilage Repair Market to Reach US$2.1 Billion by 2032

The global market for Knee Cartilage Repair estimated at US$1.7 Billion in the year 2025, is expected to reach US$2.1 Billion by 2032, growing at a CAGR of 3.6% over the analysis period 2025-2032. Autologous Chondrocytes Cell Source, one of the segments analyzed in the report, is expected to record a 3.0% CAGR and reach US$783.6 Million by the end of the analysis period. Growth in the Allogeneic Chondrocytes Cell Source segment is estimated at 2.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$511.9 Million While China is Forecast to Grow at 6.8% CAGR

The Knee Cartilage Repair market in the U.S. is estimated at US$511.9 Million in the year 2025. China, the world`s second largest economy, is forecast to reach a projected market size of US$520.8 Million by the year 2032 trailing a CAGR of 6.8% over the analysis period 2025-2032. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.6% and 2.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.2% CAGR.

Global Knee Cartilage Repair Market - Key Trends & Drivers Summarized

How Are New Surgical Techniques Transforming the Knee Cartilage Repair Market?
The knee cartilage repair market is witnessing a transformation, driven by the development of new surgical techniques and minimally invasive procedures that improve patient outcomes and reduce recovery times. Traditional approaches to cartilage repair, such as microfracture surgery and autologous chondrocyte implantation (ACI), are being enhanced by next-generation techniques, including matrix-induced autologous chondrocyte implantation (MACI), osteochondral allograft transplantation, and stem cell-based therapies. These advanced techniques provide more effective and durable solutions for cartilage repair by promoting better integration of new cartilage tissue and reducing the risk of post-operative complications. As the demand for minimally invasive and biologic treatments grows, healthcare providers are increasingly adopting these innovative techniques, driving the market for knee cartilage repair.

Why Is There an Increasing Demand for Biologic and Regenerative Therapies in Knee Cartilage Repair?
The demand for biologic and regenerative therapies in knee cartilage repair is on the rise as patients and healthcare providers seek more natural and long-lasting solutions for cartilage injuries. Biologic therapies, such as platelet-rich plasma (PRP), mesenchymal stem cell (MSC) therapy, and growth factor-based treatments, are gaining popularity due to their potential to accelerate healing, reduce inflammation, and regenerate damaged cartilage. These therapies offer significant advantages over traditional approaches by utilizing the body’s own regenerative capabilities to restore knee function. As awareness about the benefits of biologic treatments grows, there is an increasing shift towards these therapies in both clinical practice and patient preference, which is positively impacting the knee cartilage repair market.

What Role Does an Aging Population Play in Driving Market Growth?
An aging population is playing a critical role in driving the growth of the knee cartilage repair market. As the global population ages, the incidence of knee-related conditions, such as osteoarthritis and degenerative cartilage injuries, is increasing. Older adults are more susceptible to cartilage wear and tear due to age-related degeneration, leading to a growing demand for effective and minimally invasive repair solutions. Moreover, there is a rising trend among aging individuals to remain active and maintain a high quality of life, which further drives the demand for advanced cartilage repair procedures. This demographic shift is creating a significant market opportunity for manufacturers of knee cartilage repair products and providers of specialized surgical services.

How Is the Growth in the Knee Cartilage Repair Market Driven by Several Factors?
The growth in the knee cartilage repair market is driven by several factors, including advancements in surgical techniques, increasing adoption of biologic and regenerative therapies, and a growing aging population. The development of innovative procedures, such as MACI and stem cell therapies, is enhancing the effectiveness and safety of cartilage repair, attracting both surgeons and patients. The rising demand for biologic treatments that offer natural healing and reduced recovery times is also fueling market growth. Additionally, the increase in sports-related injuries and a greater emphasis on maintaining joint health among older adults are driving demand for knee cartilage repair solutions. The expansion of healthcare infrastructure and growing investment in orthopedic research and development are further contributing to the market`s robust growth outlook.

SCOPE OF STUDY:

The report analyzes the Knee Cartilage Repair market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Cell Source (Autologous Chondrocytes Cell Source, Allogeneic Chondrocytes Cell Source, Mesenchymal Stem Cell Source, Acellular Biologic Grafts Cell Source); Biomaterial (Collagen-based Biomaterial, Hyaluronic-Acid / Chitosan Biomaterial, Synthetic Polymer Biomaterial, Ceramic / Composite Biomaterial, 3-D Bioprinted Osteochondral Scaffolds Biomaterial); Application (Arthroscopic Chondroplasty Application, Microfracture Application, Osteochondral Graft Application, Autologous Chondrocyte Implantation Application, Cell-based Cartilage Resurfacing Application, Other Applications); End-Use (Hospitals End-Use, Ambulatory Surgery Centers End-Use, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

SELECT PLAYERS -

• B. Braun Melsungen AG
• DePuy Synthes
• Histogenics Corporation
• ISTO Biologics
• Medipost Co., Ltd.
• Osiris Therapeutics, Inc.
• Smith & Nephew PLC
• Stryker Corporation
• TiGenix NV
• Vericel Corporation
• Zimmer Biomet Holdings, Inc.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher. Show more